期刊
CLINICAL INFECTIOUS DISEASES
卷 72, 期 2, 页码 351-356出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciaa1079
关键词
COVID-19; SARS-CoV-2; cancer; malignancy; immunosuppresion
资金
- National Institutes of Health, National Cancer Institute, Cancer Center CORE [16672]
- Division of Intramural Research of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health
- Horizon 2020 HDM-FUN [847507]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001175, ZIAAI001318] Funding Source: NIH RePORTER
Not all cancer patients are equally at risk for severe COVID-19 complications, as factors other than cancer or its treatment may play a significant role. Further research is needed to understand the impact of COVID-19 on this heterogeneous population of patients.
Cancer patients are traditionally considered at high risk for complicated respiratory viral infections, due to their underlying immunosuppression. In line with this notion, early case series reported high mortality rates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with malignancy. However, subsequent large, prospective, epidemiological surveys indicate that the risk for severe coronavirus disease 2019 (COVID-19) may be largely attributed to the multiple confounders operating in this highly heterogeneous population of patients, rather than the cancer or its treatment per se. We critically discuss the conundrums of SARS-CoV-2 infection in cancer patients and underscore mechanistic insights on the outcome of COVID-19 as it relates to cancer therapy and the type and status of the underlying malignancy. Not all cancer patients are similarly at risk for a complicated COVID-19 course. A roadmap is needed for translational and clinical research on COVID-19 in this challenging group of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据